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A role for astroglia in pr ion diseases
In this issue of JEM, Krejciova et al. (https ://doi .org /10 .1084 /jem .20161547) report that astrocytes derived from human iPSCs 
can replicate human CJD prions. These observations provide a new, potentially very valuable model for studying human prions 
in cellula and for identifying antiprion compounds that might serve as clinical candidates. Furthermore, they add to the 
evidence that astrocytes may not be just innocent bystanders in prion diseases.
Prions are the infectious agents that 
cause Creutzfeldt–Jakob disease (CJD) 
and other fatal neurodegenerative disor-
ders affecting both humans and animals. 
Prions consist of PrPSc, a pathological 
isoform of the cellular prion protein 
PrPC that is expressed in neurons, astro-
cytes, and oligodendrocytes of the adult 
brain. Nucleation and self-sustained 
propagation of PrPSc is the major event 
driving the progression of prion diseases 
(Aguzzi et al., 2008). Although prion 
diseases are rare, they are invariably le-
thal, and no disease-modifying therapies 
exist. This sad situation is compounded 
by a dearth of validated therapeutic tar-
gets, which stems from our incomplete 
understanding of the biochemical and 
cellular networks involved in the patho-
genesis (Aguzzi et al., 2017). Because 
of the gaps in our understanding of the 
mechanisms underlying prion replica-
tion, propagation, and neurotoxicity, pri-
ons continue to represent a significant 
threat to public health. Now, a study by 
a coalition of Scottish laboratories (see 
Krejciova et al. in this issue) has provided 
new tools and interesting insights into 
the aforementioned issues.
The rationale for studying prion 
diseases goes beyond the goal of provid-
ing therapeutic options because prions 
yield a robust and flexible model for 
studying general pathways of neuro-
degeneration in the context of protein 
aggregation disease. You see, when lab-
oratory mice are infected with prions, 
they develop a disease that has all the 
characteristics of naturally occurring 
mammalian prion diseases, including 
the typical histological triad of neuronal 
loss, spongiosis, and reactive gliosis. This 
is not true for animal models of other 
neurodegeneration such as Alzheimer’s, 
Parkinson’s, and other diseases. APP 
transgenic mice, for example, develop 
amyloid plaques consisting of Aβ aggre-
gates, yet do not reproduce many other 
aspects of Alzheimer’s disease. Hence, 
one may argue that the mechanism ac-
tive in neurodegeneration (such as mi-
croglia and astrocyte activation) may be 
best studied in prion infection models 
and then tested in other protein aggre-
gation diseases.
For all their advantages, however, 
animal models of prion disease do not 
allow full dissection of the causal chain 
of events underlying prion replication 
and toxicity; in vitro models are essen-
tial to reach these goals. Although cer-
tain neuroblastoma cell lines were found 
to replicate prions (Enari et al., 2001; 
Klöhn et al., 2003), none of these lines 
appear to experience overt neurotoxic-
ity as a consequence (Li et al., 2010).
Against this backdrop, prion-in-
fectible human cell lines would be 
desirable for advancing the understand-
ing of human prion diseases and for 
developing therapeutic interventions. 
However, such experimental systems 
have been surprisingly elusive: none 
of the most popular cell lines allows 
for replication of human CJD prions, 
which may substantially differ from 
other prion strains. An early report that 
SH-SY5Y neuroblastoma cells can be 
infected with human prions seems du-
bious because these cells express only 
trace amounts of PrPC (unpublished 
observations). These limitations have 
hampered the mechanistic study of 
human prion diseases and may have 
also hindered the discovery of human 
therapies because many antiprion com-
pounds are only effective in specific an-
imal species (Aguzzi and Polymenidou, 
2004; Bolognesi and Legname, 2015; 
Aguzzi et al., 2017).
Krejciova et al. (2017) have found 
that human CJD brain extracts can elicit 
prion replication in astrocytes that were 
grown out of human induced pluri-
potent stem cells (iPSCs; see figure). 
A common Met/Val polymorphism at 
codon 129 of the PRNP gene controls 
susceptibility of humans to prion in-
fections, with homozygous individuals 
(Met/Met and Val/Val) being overrep-
resented in collectives of CJD patients. 
Moreover, variant CJD, which is thought 
to represent the transmission of bovine 
spongiform encephalopathy (“mad cow 
disease”) to humans, has almost exclu-
sively affected homozygous Met/Met 
individuals. This finding was replicated 
in the iPSC-derived astrocytes. In view 
of the potentially unlimited supply of 
genetically homogeneous iPSC-derived 
astrocytes, this model might become 
useful for screening chemical librar-
ies for compounds that inhibit human 
prion replication.
The new findings also provide ad-
ditional evidence that astrocytes might 
contribute to the pathogenesis of prion 
diseases. Previous studies had suggested 
that PrPSc deposits in astrocytes during 
prion infection both in human and in 
rodents (Diedrich et al., 1991; Kovács et 
al., 2005). Also, we and others had re-
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ported that PrnpZH1/ZH1 mice (Büeler et 
al., 1993) expression a PrPC transgene 
driven by a glial fibrillary acidic pro-
tein (GFAP) promoter exhibited prion 
replication in vivo (Raeber et al., 1997) 
with PrPSc accumulating in astrocytes 
(Jeffrey et al., 2004). Although these 
studies suggested that astrocytes may 
directly contribute to prion replica-
tion and propagation, we deemed them 
somewhat dubious (including those to 
which we had contributed) because the 
GFAP promoter fragment used for the 
generation of these mice was later found 
to be ectopically active in certain neu-
ronal populations (Marino et al., 2000; 
Zhuo et al., 2001; Casper and McCarthy, 
2006), thereby sowing doubts whether 
prion replication occurred truly in as-
trocytes. The unambiguous replication 
of CJD prions in human iPSC-derived 
astrocytes goes a long way toward vin-
dicating the Raeber publication, yet the 
astrocytes used by Krejciova et al. (2017), 
like those from any other iPSC-based 
systems, may be contaminated with 
small numbers of neuronal cells. Com-
plete, reliable elimination of all contam-
inating neurons would be desirable but 
may not be technically attainable.
Krejciova’s findings may provide a 
tool to address a long-standing enigma: 
why is it that some cell types support 
prion replication whereas others do not, 
despite high levels of PrPC expression? 
Perhaps the assembly of infectious prions 
requires a molecular nanomachine (the 
“prion replicase”) that is only present in 
certain cell types. Alternatively, replica-
tion-incompetent cells may clear prions 
more efficiently than others. In some in 
vitro systems, prion clearance may be as 
simple as prion dilution: if cells divide 
faster than they can replicate prions, the 
latter will over time become inevitably 
diluted. In contrast with the differenti-
ated astrocytes, human iPSC-derived as-
trocyte precursor cells (APCs) failed to 
support the replication of human prions 
despite expression of PrPC. This is in line 
with studies using rodents showing that 
differentiated neurons and astrocytes, but 
neither undifferentiated neurospheres 
nor oligodendrocytes, support prion 
replication (Cronier et al., 2004; Prinz et 
al., 2004; Herva et al., 2010). The quest 
for the elusive prion replicase could 
be crucially aided by genome-wide 
siRNA and CRI SPR screens of replica-
tion-competent cell lines.
Although astrocytes are indispens-
able to the integrity of the central ner-
vous system, the Barres laboratory has 
recently shown that microglia-activated 
astrocytes can significantly contribute 
to neurotoxicity (Liddelow et al., 2017). 
These findings raise the question of 
whether prions modulate the polariza-
tion of astrocytes toward a protective 
or a toxic phenotype and whether such 
modulation is cell autonomous or re-
quires the intervention of microglia.
Prions are bona fide infectious 
agents, and prion titers can be measured 
with methods similar to those used in 
diagnostic virology. Do the iPSC-de-
rived astrocytes indeed replicate prion 
(a) Human iPSC-derived astrocyte supports the replication of CJD prions. In contrast to 
differentiated astrocytes, however, human iPSC-derived APCs failed to replicate human 
prions despite expression of PrPC. It is still unclear whether human iPSC-derived neurons, 
oligodendrocytes, and their precursors (NPC and OPC, respectively) are capable of 
supporting human prion replication. (b) Rodent studies have showed that differentiated 
neurons and astrocytes, but neither undifferentiated neurospheres nor oligodendrocytes, 
support prion replication.
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infectivity, or do they simply store exog-
enous infectivity without multiplying it? 
The presence of prions is often equated 
with the appearance of proteinase K–
resistant PrP, yet prion infectivity can 
exist in the absence of protein resistance 
(Leske et al., 2017) and vice versa (Giles 
et al., 2017). The Scottish authors have 
addressed this issue by testing whether 
prion-infected astrocytes would trans-
mit the infection to a second generation 
of naive astrocytes. This is an important 
test, which should always be performed 
before claiming that any protein aggre-
gate (be it composed of Aβ, synuclein, 
tau, or else) is a “prion.” Ideally, the 
multiplication of the agent should be 
proved by rigorous titration experiment 
of input and output prions, e.g., by lim-
iting dilution.
A more specialized question relates 
to the maintenance of “strainness.” Pri-
ons come in the form of many differ-
ent strains, each one of which displays 
heritable, specific incubation times and 
target areas in the brain. The physico-
chemical underpinnings of strainness 
are likely specified by the conformation 
of PrPSc aggregates (Sigurdson et al., 
2007), which may be switched by pas-
sage through specific cell types. It will be 
interesting to assess whether astrocytes 
impose specific constraints onto the 
conformation of replicated prions. Fi-
nally, it is conceivable that astrocytes and 
neurons potentiate the toxicity of prions 
by amplifying prions produced by each 
other in a ping-pong mechanism.
In summary, the availability of a 
new cellular model of prion infection 
extends the toolbox available for prion 
science and enables a range of poten-
tially important experiments. Because 
studies of human genetics have thus 
far failed to identify any risk factors for 
prion diseases other than the PRNP 
gene itself, cell lines may contribute to 
filling that gap—in conjunction with 
modern technologies such as bar-coded 
CRI SPR libraries and next-gen se-
quencing. The brief report of Krejciova 
et al. (2017) may therefore contribute to 
the basic understanding of human prion 
replication and to accelerating drug de-
velopment for human prion diseases.
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